{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:59:00Z","timestamp":1773727140184,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.ejphar.2004.07.062","type":"journal-article","created":{"date-parts":[[2004,8,21]],"date-time":"2004-08-21T13:11:34Z","timestamp":1093093894000},"page":"9-18","source":"Crossref","is-referenced-by-count":41,"title":["Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine"],"prefix":"10.1016","volume":"498","author":[{"given":"Guido","family":"Bocci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Marangoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Fioravanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"Boggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Fasciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Boschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Campani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Generoso","family":"Bevilacqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Del Tacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2004.07.062_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.37382","article-title":"Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality","volume":"29","author":"Abbruzzese","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejphar.2004.07.062_bib2","first-page":"8890","article-title":"Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects","volume":"63","author":"Abdollahi","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2004.07.062_bib3","first-page":"1996","article-title":"Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer","volume":"62","author":"Baker","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2004.07.062_bib4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11912-003-0113-8","article-title":"Chemotherapeutic advances in pancreatic cancer","volume":"5","author":"Berlin","year":"2003","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejphar.2004.07.062_bib5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/molehr\/7.8.771","article-title":"In-vitro evidence of autocrine secretion of vascular endothelial growth factor by endothelial cells from human placental blood vessels","volume":"7","author":"Bocci","year":"2001","journal-title":"Mol. Hum. Reprod."},{"key":"10.1016\/j.ejphar.2004.07.062_bib6","first-page":"42","article-title":"Schedule-dependent antitumor effect of gemcitabine in in vivo model system","volume":"22","author":"Braakhuis","year":"1995","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejphar.2004.07.062_bib7","first-page":"4727","article-title":"Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract","volume":"53","author":"Brown","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2004.07.062_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/ijc.10681","article-title":"Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice","volume":"102","author":"Bruns","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2004.07.062_bib9","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/00000658-200212000-00006","article-title":"VEGF-RII influences the prognosis of pancreatic cancer","volume":"236","author":"Buchler","year":"2002","journal-title":"Ann. Surg."},{"key":"10.1016\/j.ejphar.2004.07.062_bib10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1083\/jcb.119.3.629","article-title":"Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth","volume":"119","author":"Bussolino","year":"1992","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejphar.2004.07.062_bib11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF00685668","article-title":"Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro","volume":"31","author":"Chou","year":"1993","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2004.07.062_bib12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0968-0004(03)00193-2","article-title":"VEGF-receptor signal transduction","volume":"28","author":"Cross","year":"2003","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejphar.2004.07.062_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2407-3-3","article-title":"Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification","volume":"3","author":"DePrimo","year":"2003","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2004.07.062_bib14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","article-title":"Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms","volume":"18","author":"Erber","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.ejphar.2004.07.062_bib15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2004.07.062_bib16","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/blood-2002-10-2998","article-title":"A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia","volume":"102","author":"Fiedler","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2004.07.062_bib17","first-page":"99","article-title":"SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types","volume":"59","author":"Fong","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2004.07.062_bib18","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0959-8049(98)00069-0","article-title":"Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis","volume":"34","author":"Fujimoto","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2004.07.062_bib19","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/cncr.11315","article-title":"Phase II study of SU5416\u2014a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor\u2014in patients with refractory myeloproliferative diseases","volume":"97","author":"Giles","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejphar.2004.07.062_bib20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9394(03)00101-6","article-title":"Treatment of von Hippel\u2013Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas","volume":"136","author":"Girmens","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejphar.2004.07.062_bib21","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/sj.bjc.6690248","article-title":"Prognostic significance of angiogenesis in human pancreatic cancer","volume":"79","author":"Ikeda","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2004.07.062_bib22","first-page":"1309","article-title":"Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression","volume":"3","author":"Itakura","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2004.07.062_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/(SICI)1097-0215(20000101)85:1<27::AID-IJC5>3.0.CO;2-8","article-title":"Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer","volume":"85","author":"Itakura","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2004.07.062_bib24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/cncr.10756","article-title":"Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations","volume":"95","author":"Jacobs","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ejphar.2004.07.062_bib25","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.4161\/cbt.213","article-title":"Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived\u2014but they can be improved","volume":"2","author":"Kerbel","year":"2003","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejphar.2004.07.062_bib26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrc905","article-title":"Clinical translation of angiogenesis inhibitors","volume":"2","author":"Kerbel","year":"2002","journal-title":"Nat. Rev., Cancer"},{"key":"10.1016\/j.ejphar.2004.07.062_bib27","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S0959-8049(00)00092-7","article-title":"\u2018Accidental\u2019 anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples","volume":"36","author":"Kerbel","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2004.07.062_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1533-0028(11)70081-0","article-title":"Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer","volume":"3","author":"Klem","year":"2003","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.ejphar.2004.07.062_bib29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00006676-199901000-00012","article-title":"Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer","volume":"18","author":"Kuehn","year":"1999","journal-title":"Pancreas"},{"key":"10.1016\/j.ejphar.2004.07.062_bib30","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.20.6.1657","article-title":"Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors","volume":"20","author":"Kuenen","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2004.07.062_bib32","first-page":"1648","article-title":"Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma","volume":"9","author":"Kuenen","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2004.07.062_bib31","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2003.08.046","article-title":"Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416","volume":"21","author":"Kuenen","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2004.07.062_bib33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1476-5586(03)80007-6","article-title":"Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin","volume":"5","author":"Lund","year":"2003","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejphar.2004.07.062_bib34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1634\/theoncologist.8-2-149","article-title":"The medical management of pancreatic cancer: a review","volume":"8","author":"McKenna","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.ejphar.2004.07.062_bib35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0959-8049(98)00387-6","article-title":"Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma","volume":"35","author":"Meister","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2004.07.062_bib36","first-page":"29","article-title":"Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent","volume":"15","author":"Mendel","year":"2000","journal-title":"Anticancer Drug Des."},{"key":"10.1016\/j.ejphar.2004.07.062_bib37","first-page":"305","article-title":"Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition","volume":"948","author":"Nagy","year":"1989","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2004.07.062_bib38","first-page":"376","article-title":"Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining","volume":"55","author":"Nagy","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2004.07.062_bib39","first-page":"5451","article-title":"Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells","volume":"60","author":"Ng","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2004.07.062_bib40","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00006676-200208000-00002","article-title":"High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas","volume":"25","author":"Niedergethmann","year":"2002","journal-title":"Pancreas"},{"key":"10.1016\/j.ejphar.2004.07.062_bib41","first-page":"5209","article-title":"Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors","volume":"59","author":"Prewett","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2004.07.062_bib42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/43.4.7534783","article-title":"Ultrastructural localization of vascular permeability factor\/vascular endothelial growth factor (VPF\/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium","volume":"43","author":"Qu","year":"1995","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.ejphar.2004.07.062_bib43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/A:1023893931057","article-title":"Pancreatic tumor growth is regulated by the balance between positive and negative modulators of angiogenesis","volume":"5","author":"Schuch","year":"2002","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ejphar.2004.07.062_bib44","first-page":"5412","article-title":"Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis","volume":"59","author":"Shaheen","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2004.07.062_bib45","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/108497801753354267","article-title":"Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787\/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases","volume":"16","author":"Solorzano","year":"2001","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.ejphar.2004.07.062_bib46","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.1016\/S0360-3016(03)01194-5","article-title":"SU5416 and SU6668 decrease angiogenic effects of radiation-induced factor productions by tumor cells and amplify the direct anti-endothelial action of radiation in vitro","volume":"57","author":"Trinh","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejphar.2004.07.062_bib47","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3748\/wjg.v9.i9.2100","article-title":"Correlation of CT enhancement, tumor angiogenesis and pathologic grading of pancreatic carcinoma","volume":"9","author":"Wang","year":"2003","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2004.07.062_bib48","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ijc.2910190118","article-title":"Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase","volume":"19","author":"Yunis","year":"1977","journal-title":"Int. J. Cancer"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299904007952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299904007952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T20:28:43Z","timestamp":1549312123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299904007952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":48,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0014299904007952"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2004.07.062","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}